ArriVent BioPharma, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • January 22nd, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
Goldman Sachs & Co. LLC Jefferies LLC Citigroup Global Markets Inc. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto,
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 16, 2022, by and among ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Indemnification AgreementIndemnification Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”) is made and entered into this [__]th day of [____], 202[ ], by and between ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and [___________] (“Indemnitee”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION AGREEMENT (the “Agreement”) is effective as of December 21, 2021 (the “Effective Date”) by and between Aarvik Therapeutics, Inc., a company incorporated in Delaware, having a place of business at 31363 Medallion Drive, Hayward, CA 94544 (“Aarvik”), and ArriVent Biopharma, Inc., a company incorporated in Delaware, with offices located at 18 Campus Blvd. Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”). ArriVent and Aarvik are referred to herein individually, as a “Party” or, collectively, as “Parties.”
CLINICAL COLLABORATION AGREEMENTClinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • New York
This CLINICAL COLLABORATION AGREEMENT (this “Agreement”) is entered into as of June 23, 2023 (the “Effective Date”), by and between ArriVent BioPharma Inc., having an address at 18 Campus Blvd., Suite 100, Newtown Square, PA 19073-3269 (“ArriVent”), and Beijing InnoCare Pharma Tech Co., Ltd., having an address at Building 8, No. 8 Life Science Park Road, ZGC Life Science Park, Changping District, Beijing, China 102206 (“InnoCare”). ArriVent and InnoCare are each referred to herein individually as “Party” and collectively as “Parties”.
JOINT CLINICAL COLLABORATION AGREEMENTJoint Clinical Collaboration Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations
This Joint Clinical Collaboration Agreement (the “Collaboration Agreement”), dated and effective as of [DATE] (the “Effective Date”), is by and between Shanghai Allist Pharmaceuticals Co., Ltd., (“Allist”) a limited liability company incorporated under the laws of China, having its principal place of business at No. 1118 Halei Road, Pudong New District, Shanghai, China; and ArriVent BioPharma, Inc. (“ArriVent”), a Delaware corporation, at 18 Campus Blvd. Suite 100, Newport P.A. (each a Party; collectively, Parties.)
GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT between ArriVent Biopharma, Inc. and Shanghai Allist Pharmaceuticals Co., Ltd.Global Technology Transfer and License Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
This GLOBAL TECHNOLOGY TRANSFER AND LICENSE AGREEMENT (this “Agreement”) is effective from the Effective Date by and between:
